Clinical Trials Arena: Alphyn gears up for Phase IIb trial for dermatitis treatment
by Abigail Beaney
Maryland-based Alphyn Biologics announced that the second cohort in its Phase IIa trial evaluating zabalafin hydrogel (AB-101a) in AD and infected AD skin met all its endpoints.
CEO Neal Koller said that based on the results from both cohorts in the Phase IIa trial, the company is preparing for a global Phase IIb trial of its lead candidate in AD which will initiate in the second half of 2024.
CONTACTS
Corporate:
Neal Koller
nkoller@alphynbiologics.com
(410) 690-8687
Media:
Susan Thomas
susan@endpointcommunications.net
(619) 540-9195